A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

This study is a clinical trial, which means it's a carefully planned way of testing new treatments to see if they are safe and effective for people with certain medical conditions. The main focus of this particular study is a new drug called IDE849. Researchers want to understand everything about IDE849: how safe it is, how the body uses and gets rid of it, if it causes any side effects, and most importantly, if it can help slow down or shrink certain types of cancer.

The cancers being looked at in this study all share a common feature: they have a special marker on their cells called DLL3. These cancers include small cell lung cancer (SCLC), which is a specific type of lung cancer, some types of neuroendocrine cancers, and other solid tumours that have this DLL3 marker. The study will test IDE849 in two ways: sometimes on its own, and sometimes combined with other medications that are either already approved or also being investigated (like durvalumab or IDE161). The hope is that IDE849, alone or in combination, could offer a new treatment option for people with these cancers.

This study has two main parts. The first part, called 'Dose Escalation,' is about finding the right dose of IDE849 that is both safe and has the best chance of working. Researchers will start with small doses and gradually increase them, carefully watching for any side effects. Once a good dose is found, the second part, called 'Dose Expansion,' will involve more people receiving this dose to gather more information on its safety and how well it works against the cancer. This phased approach helps ensure patient safety while finding the most effective treatment plan.